Further re Aivlosin research

May 2009


                           ECO Animal Health Group plc

                         Further re: Aivlosin® research


Dr David Brown and his team at the Virology Division of the Department of
Pathology at the University of Cambridge have been awarded a grant of £500,000
by the Medical Research Council to investigate the inhibition of influenza
viruses by macrolide antibiotics.

During earlier studies funded by Eco Animal Health (Eco), it has been discovered
that Aivlosin®, Eco's patented macrolide antibiotic, appears to prevent the
replication of certain common viruses including influenza in laboratory test
systems without damaging cell cultures.

Eco and the University of Cambridge entered a collaborative research agreement
in 2006 to investigate these new potential indications for Aivlosin® which is
currently licensed for respiratory and enteric bacterial diseases in pigs and
poultry.

These unexpected findings have formed the basis of patent filings as well as Eco
and Cambridge Enterprise, the University's commercialisation office, signing
licensing agreements to jointly exploit these discoveries.


Contacts:
ECO  Animal Health Group plc                 Marc Loomes   020 8447 8899

Spiro Financial                              Anthony Spiro 020 8336 6196

Cenkos  Securities plc                       Stephen Keys  020 7397 8926
(Nominated  Adviser)                     Elizabeth Bowman  020 7397 8928


ECO  Animal  Health Group plc is a leader in the development,  registration  and
marketing of pharmaceutical products for animals. Our products for these  global
growth markets promote well-being. Our financial goals are achieved through  the
careful  and  responsible  application of science  to  generate  value  for  our
shareholders.